Mark Shackleton

27.8k total citations · 5 hit papers
90 papers, 8.0k citations indexed

About

Mark Shackleton is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Mark Shackleton has authored 90 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 35 papers in Molecular Biology and 22 papers in Immunology. Recurrent topics in Mark Shackleton's work include Melanoma and MAPK Pathways (18 papers), Cutaneous Melanoma Detection and Management (17 papers) and Cancer Cells and Metastasis (17 papers). Mark Shackleton is often cited by papers focused on Melanoma and MAPK Pathways (18 papers), Cutaneous Melanoma Detection and Management (17 papers) and Cancer Cells and Metastasis (17 papers). Mark Shackleton collaborates with scholars based in Australia, United States and United Kingdom. Mark Shackleton's co-authors include Elsa Quintana, Sean J. Morrison, François Vaillant, Julia Stingl, Geoffrey J. Lindeman, Jane E. Visvader, Marie-Liesse Asselin-Labat, Timothy M. Johnson, Douglas R. Fullen and Michael S. Sabel and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Mark Shackleton

80 papers receiving 7.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Generation of a functional mammary gland from a single stem cell

2006 1.5k citations Mark Shackleton, François Vaillant et al. profile →
Efficient tumour formation by single human melanoma cells

2008 1.3k citations Elsa Quintana, Mark Shackleton et al. profile →
Purification and unique properties of mammary epithelial stem cells

2006 1.2k citations Julia Stingl, Mark Shackleton et al. profile →
Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution

2009 871 citations Mark Shackleton, Elsa Quintana et al. profile →
Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation

2006 659 citations Marie-Liesse Asselin-Labat, Mark Shackleton et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Shackleton Australia	28	5.4k	4.4k	1.9k	1.1k	922	90	8.0k
Anne‐Marie Mes‐Masson Canada	50	2.7k 0.5×	4.4k 1.0×	1.9k 1.0×	1.3k 1.2×	1.2k 1.3×	272	9.1k
Pascal Finetti France	52	4.9k 0.9×	4.7k 1.1×	3.5k 1.9×	1.5k 1.4×	1.3k 1.4×	175	9.8k
Hartmut Koeppen United States	51	5.0k 0.9×	4.9k 1.1×	1.7k 0.9×	1.4k 1.3×	1.5k 1.7×	116	9.2k
Don X. Nguyen United States	26	4.0k 0.7×	4.0k 0.9×	2.4k 1.3×	777 0.7×	1.6k 1.7×	55	8.1k
William Matsui United States	54	5.3k 1.0×	6.1k 1.4×	1.7k 0.9×	1.7k 1.5×	560 0.6×	154	10.8k
Piero Dalerba United States	26	7.4k 1.4×	6.7k 1.5×	3.6k 1.9×	1.7k 1.6×	768 0.8×	47	11.8k
J. William Harbour United States	57	5.5k 1.0×	7.0k 1.6×	1.6k 0.8×	2.3k 2.1×	1.3k 1.4×	198	13.3k
Thea D. Tlsty United States	50	4.9k 0.9×	5.7k 1.3×	2.8k 1.5×	819 0.8×	776 0.8×	109	10.6k
Nicholas McGranahan United Kingdom	34	4.0k 0.7×	4.5k 1.0×	4.5k 2.4×	1.4k 1.3×	1.9k 2.0×	67	9.4k
Antonio Jimeno United States	39	3.5k 0.6×	3.5k 0.8×	1.3k 0.7×	1.0k 1.0×	1.4k 1.5×	169	7.2k

Countries citing papers authored by Mark Shackleton

Since Specialization

Citations

This map shows the geographic impact of Mark Shackleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Shackleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Shackleton more than expected).

Fields of papers citing papers by Mark Shackleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Shackleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Shackleton. The network helps show where Mark Shackleton may publish in the future.

Co-authorship network of co-authors of Mark Shackleton

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Shackleton. A scholar is included among the top collaborators of Mark Shackleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Shackleton. Mark Shackleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fedele, Clare G., Ralph Rossi, Jason Li, et al.. (2025). Prospective Isolation According to Melanin Pigment Content of Melanoma Cells With Heterogeneous Potentials for Disease Propagation. Pigment Cell & Melanoma Research. 38(4). e70011–e70011. 1 indexed citations

Chu, Simon, Eng Hseon Tay, Kate Jones, et al.. (2025). Tiered approach to molecular testing of thyroid fine needle aspiration samples may improve preoperative diagnosis. European Journal of Surgical Oncology. 51(9). 110082–110082. 1 indexed citations

Marshall, Vikki M., Frank Lin, David M. Thomas, et al.. (2024). Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases. Clinical and Translational Medicine. 14(4). e1657–e1657. 1 indexed citations

Butler, Marcus O., Ryan Weight, Rizwan Haq, et al.. (2024). 1139TiP IDE196 (darovasertib) in combination with crizotinib versus investigator’s choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma. Annals of Oncology. 35. S747–S747. 2 indexed citations

Joshua, Anthony M., Roderick O’Day, William Glasson, et al.. (2024). A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.. Journal of Clinical Oncology. 42(16_suppl). 9510–9510. 4 indexed citations

Melero, Ignacio, Judy S. Wang, Martin Gutierrez, et al.. (2024). Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.. Journal of Clinical Oncology. 42(16_suppl). 2588–2588. 1 indexed citations

Andrews, Miles C., Roy E. Smith, Mark Edinger, et al.. (2023). Design, optimisation and standardisation of a high‐dimensional spectral flow cytometry workflow assessing T‐cell immunophenotype in patients with melanoma. Clinical & Translational Immunology. 12(9). e1466–e1466. 3 indexed citations

Zhang, Youfang, Samar Masoumi-Moghaddam, Clare G. Fedele, et al.. (2023). UHRF1/UBE2L6/UBR4-mediated ubiquitination regulates EZH2 abundance and thereby melanocytic differentiation phenotypes in melanoma. Oncogene. 42(17). 1360–1373. 9 indexed citations

Evans, Sue, Catherine A. Shang, Julie Moore, et al.. (2022). Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper. BMJ Open. 12(9). e062139–e062139.

10.

Tran, Anh, Robyn P.M. Saw, Mbathio Dieng, et al.. (2021). Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review. BMJ Open. 11(2). e040751–e040751. 15 indexed citations

11.

Zhang, Xiaomeng, Youfang Zhang, Aishwarya Kulkarni, et al.. (2020). The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. Oncogene. 39(30). 5267–5281. 61 indexed citations

12.

Zhang, Xiaomeng, Jian Tang, Ismael A. Vergara, et al.. (2019). Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma. Molecular Cancer Research. 17(7). 1435–1449. 29 indexed citations

13.

Inui, Shigeki, et al.. (2017). Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma. Molecular Cancer Therapeutics. 16(5). 936–947. 6 indexed citations

14.

Boyle, Samantha E., Clare G. Fedele, Vincent Corbin, et al.. (2016). CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity. Cancer Research. 76(13). 3965–3977. 24 indexed citations

15.

Eskiocak, Uğur, Vijayashree Ramesh, Jennifer G. Gill, et al.. (2016). Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nature Communications. 7(1). 12336–12336. 43 indexed citations

16.

Tikoo, Anjali, Vincent Roh, Karen G. Montgomery, et al.. (2012). Physiological Levels of Pik3caH1047R Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors. PLoS ONE. 7(5). e36924–e36924. 58 indexed citations

17.

Quintana, Elsa, Mark Shackleton, Hannah R. Foster, et al.. (2010). Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized. Cancer Cell. 18(5). 510–523. 446 indexed citations

18.

Shackleton, Mark, Lorraine A. O’Reilly, Mary L. Bath, et al.. (2009). Impaired lactation in mice expressing dominant‐negative FADD in mammary epithelium. Developmental Dynamics. 238(4). 1010–1016. 1 indexed citations

19.

Vaillant, François, Marie-Liesse Asselin-Labat, Mark Shackleton, et al.. (2008). The Mammary Progenitor Marker CD61/β3 Integrin Identifies Cancer Stem Cells in Mouse Models of Mammary Tumorigenesis. Cancer Research. 68(19). 7711–7717. 255 indexed citations

20.

Shackleton, Mark, François Vaillant, Kaylene J. Simpson, et al.. (2006). Generation of a functional mammary gland from a single stem cell. Cancer Research. 66. 1136–1136. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact